Mintz Levin Represents San Diego-Based MabVax Therapeutics, Inc. In IPO Through Merger with Telik, Inc.

SAN DIEGO--(BUSINESS WIRE)--

Attorneys from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.'s San Diego office represented San Diego-based MabVax Therapeutics, Inc. in its previously announced merger with a wholly owned subsidiary of Telik, Inc. TELK

Prior to the July 8^th merger, MabVax Therapeutics, Inc. was a privately-held cancer immunotherapy company focusing on the development of vaccine and antibody-based therapies for the treatment of cancer. Telik, Inc. is a publicly-traded clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. Through the transaction, the former MabVax stockholders became the controlling stockholders of the publicly-traded Telik and MabVax's management team became the management team of Telik, resulting in MabVax achieving access to the public markets through the merger.

Representing MabVax Therapeutics, Inc. in the transaction were Jeremy D. Glaser, a Member and co-chair of Mintz Levin's Venture Capital & Emerging Companies Practice and Sebastian E. Lucier, Melanie D. Ruthrauff and Jenna M. Shaffer, attorneys in the firm's Corporate & Securities Practice practicing in the San Diego office.

For more information about Mintz Levin, please visit www.mintz.com.